Identifying Comprehensive Genomic Alterations and Potential Neoantigens for Cervical Cancer Immunotherapy in a Cohort of Chinese Squamous Cell Carcinoma of the Cervix.

Biomed Environ Sci

Department of Obstetrics and Gynecology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China;Department of Obstetrics and Gynecology, Chinese PLA Medical School, Beijing 100853, China.

Published: June 2024

Objective: Genomic alterations and potential neoantigens for cervical cancer immunotherapy were identified in a cohort of Chinese patients with cervical squamous cell carcinoma (CSCC).

Methods: Whole-exome sequencing was used to identify genomic alterations and potential neoantigens for CSCC immunotherapy. RNA Sequencing was performed to analyze neoantigen expression.

Results: Systematic bioinformatics analysis showed that C>T/G>A transitions/transversions were dominant in CSCCs. Missense mutations were the most frequent types of somatic mutation in the coding sequence regions. Mutational signature analysis detected signature 2, signature 6, and signature 7 in CSCC samples. , , and were identified as potential driver genes, with as a newly reported gene. Genomic variation profiling identified 4,960 potential neoantigens, of which 114 were listed in two neoantigen-related databases.

Conclusion: The present findings contribute to our understanding of the genomic characteristics of CSCC and provide a foundation for the development of new biotechnology methods for individualized immunotherapy in CSCC.

Download full-text PDF

Source
http://dx.doi.org/10.3967/bes2024.064DOI Listing

Publication Analysis

Top Keywords

potential neoantigens
16
genomic alterations
12
alterations potential
12
neoantigens cervical
8
cervical cancer
8
cancer immunotherapy
8
cohort chinese
8
squamous cell
8
cell carcinoma
8
signature signature
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!